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Abstract 145 
Background: This study aims to investigate whether maternal SARS-CoV-2 status affect 
placental pathology. Methods: A retrospective case-control study was conducted by reviewing 
charts and slides of placentas between April 1 to July 24, 2020. Clinical history of “COVID-19” 
were searched in Pathology Database (CoPath). Controls were matched with SARS-CoV-2-
negative women  with singleton deliveries in the 3rd-trimester. Individual and group, pathological 
features were extracted from placental pathology reports. Results: Twenty-one 3rd-trimester, 
placentas from SARS-CoV-2-positive women were identified and compared to 20 placentas 
from SARS-CoV-2-negative women. There were no significant differences in individual or 
group gross or microscopic pathological features between the groups. Within the SARS-CoV-2+ 
group, there are no differences between symptomatic and asymptomatic women. Conclusion: 
Placentas from SARS-CoV-2-positive women do not demonstrate a specific pathological pattern. 
Pregnancy complicated with COVID-19 during the 3rd trimester does not have a demonstrable 
effect on placental structure and pathology.  
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Introduction 
Coronavirus disease 2019 (COVID-19) is caused by infection of SARS-CoV-2, a 
member of the betacoronavirus family. SARS-CoV-2 is a 30 kb enveloped, positive sense, 
single-stranded RNA virus. The virus consists of four structural proteins (spike surface 
glycoprotein, envelope protein, membrane protein, and nucleocapsid protein) and non-structural 
proteins. The spike protein consists of two functional subunits. The S1 subunit is responsible for 
binding to the host cell receptor and the S2 subunit is utilized for the fusion of the viral and 
cellular membranes.1,2 Studies showed that the spike protein for SARS-CoV-2 binds to 
angiotensin converting enzyme 2 (ACE2), which is also a functional receptor for SARS-CoV.  
ACE2 expression is high in lung, heart, ileum, kidney and bladder. Thus, SARS-CoV-2 virus 
primarily affects the respiratory system, although other organ systems are also involved.1 
Approximately 1% of infected people develop severe acute respiratory distress syndrome 
(ARDS) that requires a critical level of care. A MMWR study suggested that pregnant women 
with COVID-19 are more likely to be hospitalized, and are at increased risk for intensive care 
unit (ICU) admission and receipt of mechanical ventilation, compared to nonpregnant women.3 
While much remains unknown, affected respiratory function affects raise concerns regarding 
oxygenation during pregnancy.  
Studies of pregnancy outcomes associated with COVID-19 infection suggest that 
pregnant women with SARS-CoV2 infection have increased pregnancy complications.4,5 The 
placenta is the key organ at the maternal/fetal interface and is known to be the root cause for 
some pregnancy complications. The placenta essentially functions as the fetal lungs and kidneys 
and has been implicated in SARS-CoV-2 infection. Valdés G et al have reported 
immunocytochemical expression of ACE2 in the syncytiotrophoblast (ST), cytotrophoblast (CT), 
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endothelium and vascular smooth muscle of primary and secondary villi, 6 while Vivanti A et al 
demonstrated potential evidence of transplacental transmission.7 Thus, it is important to study the 
effects of SARS-CoV2 infection on placental structure and growth.  
We tested the null hypothesis that placentas in women infected at the mid-to-late stage of 
pregnancy would show no impact of the viral infection on placental structure and growth.  
 
Materials and Methods 
Institution Review Board (IRB) approval  
IRB ID# 201902092 was approved by the Office of Institution Review Board, 
Washington University in St. Louis. 
Study design 
 Retrospective case-control review charts and slides during April 1 to July 24, 2020. 
Study Patients  
Placental reports from pregnant women with positive SARS-CoV-2 testing were 
identified via the electronic health record in CoPath. They were all third trimester singleton 
deliveries during April 1st to July 24, 2020.  
Control group 
Control placentas were chosen from deliveries during April 1st to July 24, 2020. The 
pregnant women chosen were tested for SARS-CoV-2 with negative results. The first third 
trimester singleton placenta, accessioned in Histology Laboratory (in the Pathology department) 
after the identified SARS-CoV-2 + placenta, were used as study controls. The exclusion criteria 
were those without testing, with fetal anomalies, or with a multiple gestation pregnancy.  
Clinical information 
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 Clinical information was extracted from the electronic medical records (EPIC). 
Placental pathology review and central review 
All placentas were grossly examined and microscopically examined with H&E-stained 
sections, which usually included one section with two umbilical cord sections and membrane 
rolls, and three full-thickness sections that included fetal and maternal surfaces. Additional 
sections were submitted for any tissue with presumed lesions.  The placental pathology reports 
were generated by Anatomic or Pediatric Pathology (PediP) board certified pathologists 
following established criteria and were centrally reviewed by PediP board-certified 
pathologist.8,9 The slides for every case were reviewed by two pathologists.  
SARS-CoV-2 testing 
Testing for pregnant women via nasopharyngeal swabs was performed at Barnes Jewish 
Hospital Molecular Infectious Disease Laboratory. The 2019-Novel Coronavirus Assay 
(COVID-19) Real Time RT-PCR assay was used to detect the presence of SARS-CoV-2 RNA. 
Statistics 
The Shapiro–Wilks test was used to check normality of the distribution of the placental 
morphometric variables. The mean and standard deviation of each placental morphometric 
variable were obtained and mean comparisons between groups were performed using a 2-sample 
t-test or Mann–Whitney U test, as appropriate. Chi-square or Fisher’s exact test was used as 
appropriate for categorical variables. Significance was set at p<0.05. All the statistical tests were 
two-sided and performed with SAS 9.4 (SAS Inc, Cary, NC). 
Results 
A computerized Copath search yielded 21 placentas from pregnant women who tested 
positive for SARS-CoV-2 (the study group), all delivered in the third trimester between 33-40 
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weeks. Correspondingly, 20 control third trimester placentas were chosen by criteria mentioned 
in Methods (the control group). Clinical information is summarized in Table 1. There were no 
significant differences in maternal age, gestational age at delivery, placental weight, or 
fetal/placental (F/P) weight ratio between the two groups.   
Detailed histopathological features of the study group are summarized in Table 2. Among 
the 21 patients tested positive for COVID-19, seven (7/21, 33.3%) had respiratory symptoms. 
Patient #15 delivered at 34 weeks’ gestation and the infant died in seven hours. Fourteen (14/21, 
66.7%) placentas had weights that were < 10th % for gestational age, and thus, were small for 
gestational age There were no large for gestational age placentas.  
Placentas from SARS-CoV-2-positive women did not demonstrate specific pathology or 
pathological pattern. There were no significant differences in individual or group 
histopathological features between the study and control groups. In the study group, ten of 21 
placentas (47.6%) had features of maternal vascular malperfusion (MVM) which was not 
significantly different from the four of 20 placentas (20%) with MVM in the control group. 
Between the study and control groups, there were ten of 21 (47.6%) placentas in the study group 
showing any features of fetal vascular malperfusion (FVM), not significantly different from the 
eight of 20 control placentas (40%) with FVM features. There were two of 21 study group, and 
three of 20 control, placentas showing maternal inflammatory response, and two of 21 study 
group, and four of 20control, placentas showing the fetal inflammatory response (). Each of the 
two groups had one placenta with villitis of unknown etiology (VUE) and four placentas with 
chronic deciduitis with plasma cells. A single placenta, in the study group, exhibited 
T/eosinophilic vasculitis. None of these pathologies were significantly different between the two 
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groups. There were no differences in abnormal cord insertion or cord coiling between the two 
groups, not any differences in chorioamnion pathology. 
 Within the SARS-CoV-2-positive study group patients, there were seven symptomatic 
patients and fourteen asymptomatic patients. There were no significant differences between 
symptomatic and asymptomatic patients in the number placentas with SGA (5/7 vs. 9/14), 
MVM(4/7 vs 6/14),  FVM (4/7 vs 6/14), or signs of chronic inflammation reflected by chronic 
deciduitis or VUE (2/7 vs 3/14).  
  
Discussion 
Placental pathology with SARS-CoV-2 positive women 
 The data show that we must accept the null hypothesis that there is no significant 
difference in placental pathology in women tested for SARS-CoV-2, comparing those positive 
with those negative.  This differs from two case-control studies of placental pathology in patients 
who were SARS-CoV-2 positive. Shanes and associates examined15 placentas delivered in the 
third trimester in COVID positive women and reported  a high prevalence of decidual 
arteriopathy and other features of MVM.10 This study included a 16-week intrauterine fetal 
demise in which fetal tissue tested negative for SARS-CoV-2.10 Smithgall and colleagues 
demonstrated that 52 third trimester placentas from SARS-CoV-2-positive women had higher 
prevalence of villous agglutination and subchorionic thrombi, compared to placentas in the 
control group.11 None of these pathologies were more frequent in our two groups of patients 
were compared based on COVID-19 test-positivity.  In a case series, Baergen and Heller found 
that ten of 20 (10/20, 50%) cases of COVID positive patients showed some evidence of FVM or 
fetal vascular thrombosis (FTV).12  Moreover, Hecht and colleagues  examined placentas of  
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nineteen COVID-19 exposed women and found that there was no characteristic histopathology 
present among the 19 cases, despite two placental infections.13 
Our study included a control group of placentas to compare with placentas from SARS-
CoV-2 positive women, and we did not identify a specific pathology or pathological pattern 
attributed to the virus. Compared to placentas from SARS-CoV-2-negative women, there were 
no significant differences in gross and microscopic placental pathology, including placental 
weight, SGA placentas, abnormal cord insertion or cord coiling, MVM, FVM, and maternal or 
fetal inflammatory responses. Our results of no signature pathology for placentas in women 
positive for COVID-19 reflect the findings of our local obstetrical patient population in St. 
Louis, MO, from which the study subjects were derived. Populations from other locales, such as 
the ones reported in the above papers, may exhibit different placental responses that reflect 
regional differences in patient populations.  
 The microscopic findings from current study support our acceptance of the null 
hypothesis that SARS-CoV-2 infection acquired during third trimester does not have a 
demonstrable impact on placental structure and pathology. Notably, our acceptance of the null 
hypothesis is further supported by absence of significant differences in placental weight and 
fetal/placental weight ratio. Placental weight is a surrogate for placental growth and development 
while fetal/placental weight ratio is often regarded as a surrogate marker for placental efficiency.  
 We do not rule out a greater impact if the infection occurred earlier in pregnancy. 
Key issues related to pregnancy associated with COVID-19 
ACE2 in placenta 
Immunocytochemical expression of ACE2 is localized in the syncytiotrophoblast, 
cytotrophoblast, endothelium and vascular smooth muscle of primary and secondary villi.6  
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Expression of ACE2 by immunohistochemistry in placentas of COVID-19 exposed pregnancies 
showed ACE2 membranous expression polarized in the villous syncytiotrophoblast (with 
immunoreactivity highest on the stromal side of the ST). Importantly, there was also 
cytotrophoblast and extravillous trophoblast expression of ACE2. In contrast, no ACE2 
expression was detected in villous stroma, Hofbauer cells, or endothelial cells.13 ACE2 protein is 
enriched per unit volume in the placenta and ovary, compared to other tissues, despite a low 
mRNA level detected in the two tissues.14 The studies offer a potential mechanism for maternal-
fetal transmission. 
Does SARS-CoV-2 infect placenta? 
Smithgall and colleagues found  no evidence of direct viral infection of the placenta, 
using in-situ hybridization for the S-gene encoding the spike protein and immunohistochemistry 
with the monoclonal-SARS-CoV-2 spike-antibody 1A9.11 Conversely, in two of 19 cases 
reported by Hecht et al.13, SARS-CoV-2 RNA was present in placental villi focally, in both the 
ST and cytotrophoblast.13 Moreover, three of 11 placentas having swabs taken from villi and 
fetal membranes tested positive for SARS-CoV-2.15 An additional case report, of a woman who 
was infected with SARS-CoV-2 at 22 weeks gestation, showed that the placenta and umbilical 
cord were positive for SARS-CoV-2 at delivery.16 Localization of SARS-CoV-2 spike protein 
and RNA was found in both villi and peri-villous fibrin.16 Collectively, these data suggest that 
viral colonization of the placenta and fetal membranes may occur but not in a predictable 
manner. Whether colonization leads to infection remains unknown. 
Is there vertical transmission 
 Studies of vertical transmission to date have shown conflicting results,2,17   but a cautious 
conclusion is that there is minimal, if any, role for vertical transmission of the virus through the 
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placenta to the fetus. Clearly, this is a key question in understanding the impact of COVID-19 on 
maternal and neonatal morbidity and mortality. 
Placental pathology in SARS and MERS 
Verma and colleagues reviewed placental pathology associated with SARS or MERS 
infection.2 Placentas from these coronavirus viruses show acute and chronic placental 
insufficiency and associated with intrauterine growth restriction (IUGR) or miscarriage in 40% 
of affected pregnancies.18-20 However, the key issue again lies in the need for studies with a 
control group. A case in point is our study, which demonstrated almost half of the cases in the 
study group demonstrated features of maternal or fetal vascular malperfusion; however, there 
was no statistically significant difference in the study group when compared with the control 
group.  
Conclusion 
Third trimester placentas from SARS-CoV-2-positive women do not express specific 
pathology or pathological pattern. While they harbor a relatively high prevalence of features of 
maternal or fetal vascular malperfusion, these features were not unique as they were also present 
in women who had a clinical indication for SARS-CoV-19 testing with test-negative results. 
Pregnancy complicated with COVID-19 during the 3rd trimester does not have an obvious effect 
on placental structure and pathology. We do not rule out a greater impact if the infection 
occurred earlier in pregnancy. 
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Table 1. Clinical and pathological information of study and control groups 
 
 Study group 
(SARS-CoV-2 tested 
positive) 
N = 21 
Control group  
(SARS-CoV-2 tested 
positive) 
N = 20 
P value 
Maternal age (years, 
minimal to maximum, 
median) 
 
17-37,  
30 
 
18-37,  
27 
 
NS 
Gestational age at 
delivery (weeks, minimal 
to maximum, median) 
 
33-40, 
37.5 
 
28-41, 
38 
 
NS 
Placental weight (grams, 
minimal to maximum, 
median) 
 
337.5-577, 
446 
 
255-632 
432 
 
NS 
Fetal/placental weight 
ratio (mean, std dev) 
6.64 ±0.83 6.58 ±1.53 NS 
Features of maternal 
vascular malperfusion  
10 (47.6%) 4 (20%) NS 
Features of fetal vascular 
malperfusion 
10 (47.6%) 8 (40%)  
NS 
Maternal inflammatory 
response 
2 (9.5%) 3 (15%) NS 
Fetal inflammatory 
response 
2 (9.5%) 4 (20%) NS 
Chronic inflammation 
(chronic deciduitis and 
VUE) 
5 (23.8%) 5 (25%) NS 
 
NS: No significant difference. 
VUE: Villitis of unknown etiology 
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Table 2. Placental pathology in placentas from SARS-CoV-2-positive women (the study group) 
 
Patient No. 1 2 3 4 5 6 7 8 9 10 1
1 
12 13 14 15 16 17 18 1
9 
20 21 N 
(%) 
P 
 
Age (y) 35 27 27 2
7 
1
8 
32 30 31 20 17 2
1 
35 31 19 34 19 30 31 3
7 
31 34  NS 
Gestational age 
at delivery (W) 
39 39 39 3
7 
3
9 
37 39 40 39 37 3
7 
33 38 34 37 36 39 39 3
7 
37 37  NS 
Respiratory 
symptoms 
 X       X X  X   X   X  X  7 
(33.3
) 
 
Maternal 
conditions 
during this 
pregnancy 
Anemia
, 
asthma 
fever 
and 
coug
h 
"GBS+
, PN, 
flu 
N N CHTN
,  
sarcoi-
dosis 
GD
M 
GBS
+ 
HT, 
feve
r 
Loss 
of 
taste 
and 
smel
l 
PE Pneu-
monia
, RF 
GHTN
, IDA 
CHT
N 
RA, 
pneu-
moni
a 
HS
V 
GHT
N 
Asthma
, 
GBS+, 
fever 
PE Tachy
-pnea 
HCV
, 
HSV, 
Sub-
stanc
e 
abuse 
  
SGA placenta X X  X X X X  X X X   X X X   X X  14 
(66.7
) 
NS 
LGA placenta                       N/
A 
Features of 
Maternal 
vascular 
malperfusion 
 X    X    X X   X  X X X X X  10 
(47.6
) 
NS 
Decidual 
vasculopathy 
         X X   X      X   NS 
Retroplacental 
hematoma 
     X           X      NS 
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Trophoblastic 
giant cells 
 X        X X   X  X  X     NS 
Parenchymal 
infarct 
                  X    NS 
Accelerated 
villous 
maturity 
             X  X       NS 
Villous 
agglutination 
                      NS 
Abnormal cord 
insertion 
X             X      X   NS 
Hypercoiling 
of umbilical 
cord  
                      NS 
True knot of 
cord 
1             14       21  NS 
Features of 
fetal vascular 
malperfusion 
 X  X     X X    X  X X X  X X 10 
(47.6
) 
NS 
Avascular villi, 
clustered 
             X       X  NS 
Thrombi of 
fetal vessels 
                      NS 
Hemorrhagic 
endovasculitis 
                      NS 
Ectasia of 
chorionic plate 
fetal vessels 
 X  X          X    X     NS 
Chorangiosis         X X    X  X X   X   NS 
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Delayed villous 
maturation 
         X              
Villous edema             X   X       NS 
Maternal 
inflammatory 
response 
  X    X               2 
(9.5) 
NS 
Fetal 
inflammatory 
response 
  X    X               2 
(9.5) 
NS 
Acute 
chorioamnionit
is 
  X    X                NS 
Acute 
vasculitis or 
funisitis  
  X    X                NS 
Chronic 
inflammation  
 X  X            X X   X  5 
(23.8
) 
 
Chronic 
deciduitis with 
plasma cells 
 X  X            X X      NS 
VUE                    X   NS 
Other 
placental 
pathology 
                       
Intervillous 
thrombi 
                      NS 
Increased 
perivillous 
         X             NS 
 19 
 
fibrin/fibrinoid 
deposition 
 
Note: N: Normal or none. NS: No significant difference.  
CHTN: Chronic hypertension. GBS: Group B streptococcus. GDM: Gestational diabetes mellitus. GHTN: Gestational hypertension. HT: 
Hypothyroidism. IDA: Iron-deficient anemia. PE: Preeclampsia. PN: Pyelonephritis. RF: Respiratory failure.  
